Synapse

← Meletios Α. Dimopoulos

Papers by Meletios Α. Dimopoulos

Page 5 · newest first

  1. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III TrialJournal of Clinical Oncology · 2023
  2. Surgical Treatment of Solitary Metachronous Adrenal Metastasis from Urothelial Carcinoma of the Urinary BladdertouchREVIEWS in Endocrinology · 2023
  3. Belantamab mafodotin induces immunogenic cell death within 24 h post‐administration in newly diagnosed multiple myeloma patientsAmerican Journal of Hematology · 2022
  4. Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple MyelomaSHILAP Revista de lepidopterología · 2022
  5. The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple MyelomaInternational Journal of Molecular Sciences · 2022
  6. Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myelomaBritish Journal of Clinical Pharmacology · 2022
  7. Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysisFrontiers in Oncology · 2022
  8. Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s MacroglobulinemiaLeukemia · 2022
  9. Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster VaccinationCancers · 2022
  10. Managing Waldenström’s macroglobulinemia with BTK inhibitorsLeukemia · 2022
  11. An Untargeted Metabolomics Approach on Carfilzomib-Induced NephrotoxicityMolecules · 2022
  12. Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma NetworkBlood · 2022
  13. Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma NetworkBlood · 2022
  14. Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone StudyBlood · 2022
  15. Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo StudyBlood · 2022
  16. Improved Survival of Patients with Primary Plasma Cell Leukemia with VRD or Daratumumab-Based Quadruplets: A Multicenter Study By the Greek Myeloma Study GroupBlood · 2022
  17. Antibody Response to COVID-19 mRNA Vaccine in Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia after Primary Immunization and Booster: Reactivity to the Sars-Cov-2 WT Virus, Delta and Omicron VariantsBlood · 2022
  18. Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrationsBlood Advances · 2022
  19. Optimal Time Interval Between Neoadjuvant Platinum-based Chemotherapy and Interval Debulking Surgery in High-grade Serous Ovarian Cancer2022
  20. Pulmonary function tests reveal unrecognised lung dysfunction and have independent prognostic significance in patients with systemic AL amyloidosisAmyloid · 2022
  21. Subarachnoid hemorrhage in a postpartum mother: A rare manifestation of an uncommon diseaseGynecologic Oncology Reports · 2022
  22. Autophagy activation can partially rescue proteasome dysfunction‐mediated cardiac toxicityAging Cell · 2022
  23. Mineralocorticoid Receptor Pathway Is a Key Mediator of Carfilzomib-induced Nephrotoxicity: Preventive Role of EplerenoneHemaSphere · 2022
  24. Graded Cardiac Response Criteria for Patients With Systemic Light Chain AmyloidosisJournal of Clinical Oncology · 2022
  25. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trialsBlood · 2022
  26. Diagnostics in Waldenström’s Macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia2022
  27. Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted AgentsVaccines · 2022
  28. Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational StudyCurrent Oncology · 2022
  29. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 TrialJournal of Clinical Oncology · 2022
  30. Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA TherapyHemaSphere · 2022
  31. Single-cell multimodal analysis identifies common regulatory programs in synovial fibroblasts of rheumatoid arthritis patients and modeled TNF-driven arthritisGenome Medicine · 2022
  32. SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignanciesAmerican Journal of Hematology · 2022
  33. Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implicationsAmerican Journal of Hematology · 2022
  34. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomesNature Communications · 2022
  35. Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”Cancers · 2022
  36. P914: Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients With Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma NetworkHemaSphere · 2022
  37. Advances in Gynecological CancersInternational Journal of Molecular Sciences · 2022
  38. Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 PatientsJournal of Clinical Medicine · 2022
  39. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysisAmerican Journal of Hematology · 2022
  40. Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response BiomarkerSHILAP Revista de lepidopterología · 2022
  41. Physical Exercise Restrains Cancer Progression through Muscle-Derived FactorsCancers · 2022
  42. Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune ResponseCells · 2022
  43. Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple MyelomaRadiology · 2022
  44. Characterizing Kinetics and Avidity of SARS-CoV-2 Antibody Responses in COVID-19 Greek PatientsViruses · 2022
  45. Melflufen for the treatment of multiple myelomaExpert Review of Clinical Pharmacology · 2022
  46. “The emerging role of capivasertib in breast cancer”The Breast · 2022
  47. B08: A Third Bnt162b2 Dose Induces Antibody Responses Against Sars-Cov-2 Even in Previously Non-Responders With Multiple MyelomaHemaSphere · 2022
  48. The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosisInsights into Imaging · 2022
  49. Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall SurvivalFrontiers in Oncology · 2022
  50. High frequency of central nervous system involvement in transformed Waldenström macroglobulinemiaBlood Advances · 2022